K S Babu

Summary

Affiliation: University of Southampton
Country: UK

Publications

  1. ncbi request reprint Associations between procalcitonin and markers of bacterial sepsis
    Veeresh K Patil
    Level C, Respiratory Medicine, Queen Alexandra Hospital, Cosham, Portsmouth, PO6 3LY, United Kingdom
    Medicina (Kaunas) 48:383-7. 2012
  2. ncbi request reprint Role of tumor necrosis factor alpha in asthma
    K Suresh Babu
    Respiratory Cell and Molecular Biology Infection, Inflammation and Repair, Southampton General Hospital, Level D, Centre Block, Mailpoint 810, Southampton SO16 6YD, UK
    Immunol Allergy Clin North Am 24:583-97, v-vi. 2004
  3. ncbi request reprint Drug-induced airway diseases
    K Suresh Babu
    Mail Point 810, Level D, Centre Block, Southampton General Hospital, Southampton SO16 6YD, UK
    Clin Chest Med 25:113-22. 2004
  4. ncbi request reprint Aspirin and asthma
    K S Babu
    Department of Respiratory Cell and Molecular Biology, University of Southampton, Southampton General Hospital, Southampton, UK
    Chest 118:1470-6. 2000
  5. ncbi request reprint Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma
    K S Babu
    Division of Infection, Inflammation and Repair, School of Medicine, Southampton General Hospital, Southampton, UK
    Eur Respir J 21:1046-9. 2003
  6. ncbi request reprint Newer therapies for asthma: a focus on anti-IgE
    K Suresh Babu
    Respiratory Cell and Molecular Biology, Southampton General Hospital, UK
    Indian J Chest Dis Allied Sci 44:107-15. 2002
  7. ncbi request reprint Management of cutaneous drug reactions
    K S Babu
    Medical Specialities, Southampton General Hospital, Mail Point 810, Level D, Centre Block, Southampton SO16 6YD, UK
    Curr Allergy Asthma Rep 2:26-33. 2002
  8. ncbi request reprint Omalizumab, a novel anti-IgE therapy in allergic disorders
    K S Babu
    Department of Respiratory Cell and Molecular Biology, Southampton General Hospital, Southampton, UK
    Expert Opin Biol Ther 1:1049-58. 2001
  9. doi request reprint The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial
    J B Morjaria
    Infection, Inflammation and Repair Division, Southampton University Hospitals Trust, Southampton, UK
    Thorax 63:584-91. 2008
  10. pmc Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma
    P H Howarth
    Allergy and Inflammation Research, Division of Infection, Inflammation and Repair, School of Medicine, F Level South Block 810, Southampton General Hospital, Southampton SO16 6YD, UK
    Thorax 60:1012-8. 2005

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Associations between procalcitonin and markers of bacterial sepsis
    Veeresh K Patil
    Level C, Respiratory Medicine, Queen Alexandra Hospital, Cosham, Portsmouth, PO6 3LY, United Kingdom
    Medicina (Kaunas) 48:383-7. 2012
    ....
  2. ncbi request reprint Role of tumor necrosis factor alpha in asthma
    K Suresh Babu
    Respiratory Cell and Molecular Biology Infection, Inflammation and Repair, Southampton General Hospital, Level D, Centre Block, Mailpoint 810, Southampton SO16 6YD, UK
    Immunol Allergy Clin North Am 24:583-97, v-vi. 2004
    ..This article examines the role of TNF-alpha in asthma and the effects of blocking TNF-alpha as a possible therapeutic option in patients with severe corticosteroid-dependent asthma...
  3. ncbi request reprint Drug-induced airway diseases
    K Suresh Babu
    Mail Point 810, Level D, Centre Block, Southampton General Hospital, Southampton SO16 6YD, UK
    Clin Chest Med 25:113-22. 2004
    ..In view of the constantly-evolving therapies, an active policy to identify and report adverse effects is essential to develop management strategies and treatment recommendations...
  4. ncbi request reprint Aspirin and asthma
    K S Babu
    Department of Respiratory Cell and Molecular Biology, University of Southampton, Southampton General Hospital, Southampton, UK
    Chest 118:1470-6. 2000
    ..This review covers the latest understanding of pathogenesis, clinical features, and management of AIA...
  5. ncbi request reprint Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma
    K S Babu
    Division of Infection, Inflammation and Repair, School of Medicine, Southampton General Hospital, Southampton, UK
    Eur Respir J 21:1046-9. 2003
    ..Exogenous surfactant administration could serve as a useful adjunct in controlling the early allergen-induced symptoms in patients with allergic asthma...
  6. ncbi request reprint Newer therapies for asthma: a focus on anti-IgE
    K Suresh Babu
    Respiratory Cell and Molecular Biology, Southampton General Hospital, UK
    Indian J Chest Dis Allied Sci 44:107-15. 2002
    ..This review gives a brief overview of the newer therapies under investigation with special reference to omalizumab in the treatment of allergic asthma...
  7. ncbi request reprint Management of cutaneous drug reactions
    K S Babu
    Medical Specialities, Southampton General Hospital, Mail Point 810, Level D, Centre Block, Southampton SO16 6YD, UK
    Curr Allergy Asthma Rep 2:26-33. 2002
    ..The management of a cutaneous drug eruption is very much individualized, based on the clinical setting. This review aims to provide a general approach to the patient with a presumed cutaneous drug reaction...
  8. ncbi request reprint Omalizumab, a novel anti-IgE therapy in allergic disorders
    K S Babu
    Department of Respiratory Cell and Molecular Biology, Southampton General Hospital, Southampton, UK
    Expert Opin Biol Ther 1:1049-58. 2001
    ..Omalizumab also demonstrated a high level of safety in adults, adolescents and children with a side effect profile no different from the placebo. Its development is an exciting milestone in the treatment of allergic diseases...
  9. doi request reprint The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial
    J B Morjaria
    Infection, Inflammation and Repair Division, Southampton University Hospitals Trust, Southampton, UK
    Thorax 63:584-91. 2008
    ..Tumour necrosis factor alpha (TNFalpha) is a cytokine recognised as a therapeutic target in chronic inflammatory diseases...
  10. pmc Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma
    P H Howarth
    Allergy and Inflammation Research, Division of Infection, Inflammation and Repair, School of Medicine, F Level South Block 810, Southampton General Hospital, Southampton SO16 6YD, UK
    Thorax 60:1012-8. 2005
    ....
  11. pmc Absence of respiratory effects with ivabradine in patients with asthma
    K Suresh Babu
    Infection, Inflammation and Repair, Southampton General Hospital, Southampton, UK
    Br J Clin Pharmacol 66:96-101. 2008
    ..Ivabradine has been recently approved for the treatment of stable angina. This study assessed the effects of repeated administration of ivabradine on lung function in patients with asthma...
  12. ncbi request reprint The role of allergy in the development of airway inflammation in children
    K Suresh Babu
    Respiratory Cell and Molecular Biology, Southampton General Hospital, Southampton, UK
    Paediatr Respir Rev 4:40-6. 2003
    ..The persistent airway inflammation leads to tissue remodelling and airway hyperresponsiveness, the clinical sine qua non of asthma...
  13. ncbi request reprint The role of anti-IgE therapies in the treatment of asthma
    K Suresh Babu
    Department of Respiratory Cell and Molecular Biology, Southampton General Hospital, Southampton SO16 6YD
    Hosp Med 63:483-6. 2002
    ....
  14. ncbi request reprint Technology evaluation: mepolizumab, GlaxoSmithKline
    Gnanasegaram Gnanakumaran
    Mail Point 810, Level D, Centre Block, Southampton General Hospital, Southampton, SO16 6YD, UK
    Curr Opin Mol Ther 5:321-5. 2003
    ..Phase II trials in asthma were underway by April 1998 and by March 2002, phase II trials had also been initiated in atopic dermatitis...